Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) kicked off on Tuesday, up 1.94% from the previous trading day, before settling in for the closing price of $21.65. Over the past 52 weeks, CPRX has traded in a range of $13.12-$24.27.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 4106.79% over the last five years. While this was happening, its average annual earnings per share was recorded 93.39%. With a float of $105.77 million, this company’s outstanding shares have now reached $119.27 million.
The firm has a total of 167 workers. Let’s measure their productivity. In terms of profitability, gross margin is 82.32%, operating margin of 37.78%, and the pretax margin is 41.0%.
Catalyst Pharmaceuticals Inc (CPRX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Catalyst Pharmaceuticals Inc is 11.32%, while institutional ownership is 75.87%. The most recent insider transaction that took place on Dec 10 ’24, was worth 1,096,350. In this transaction Chief Op. & Scientific Officer of this company sold 50,000 shares at a rate of $21.93, taking the stock ownership to the 686,996 shares. Before that another transaction happened on Dec 10 ’24, when Company’s Officer proposed sale 50,000 for $21.93, making the entire transaction worth $1,096,333.
Catalyst Pharmaceuticals Inc (CPRX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.44 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 93.39% per share during the next fiscal year.
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) Trading Performance Indicators
Take a look at Catalyst Pharmaceuticals Inc’s (CPRX) current performance indicators. Last quarter, stock had a quick ratio of 4.92. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.72. Likewise, its price to free cash flow for the trailing twelve months is 14.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.17, a number that is poised to hit 0.34 in the next quarter and is forecasted to reach 1.59 in one year’s time.
Technical Analysis of Catalyst Pharmaceuticals Inc (CPRX)
Analysing the last 5-days average volume posted by the [Catalyst Pharmaceuticals Inc, CPRX], we can find that recorded value of 0.9 million was lower than the volume posted last year of 1.17 million. As of the previous 9 days, the stock’s Stochastic %D was 50.30%. Additionally, its Average True Range was 0.68.
During the past 100 days, Catalyst Pharmaceuticals Inc’s (CPRX) raw stochastic average was set at 75.36%, which indicates a significant increase from 54.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 28.90% in the past 14 days, which was lower than the 37.25% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $21.65, while its 200-day Moving Average is $18.21. Now, the first resistance to watch is $22.49. This is followed by the second major resistance level at $22.92. The third major resistance level sits at $23.34. If the price goes on to break the first support level at $21.64, it is likely to go to the next support level at $21.22. Now, if the price goes above the second support level, the third support stands at $20.79.
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) Key Stats
The company with the Market Capitalisation of 2.63 billion has total of 119,273K Shares Outstanding. Its annual sales at the moment are 398,200 K in contrast with the sum of 71,410 K annual income. Company’s last quarter sales were recorded 128,700 K and last quarter income was 43,880 K.
